glp-1 drugs pharmaceutical companies partnerships 2025 Compounded" | Health Communication Research Laboratory What to Make of the

doi: 10.1016/S0140-6736(64)90011-X 6 BaggioLLDruckerDJ

Both semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) are designed for once-weekly dosing and that long-acting design means they don't leave your body quickly either

Left unchecked, it can cause fatty deposits to build up in artery walls, raising the risk of heart attack, stroke and other cardiovascular disease

These drugs slow gastric emptying, raising concerns about pulmonary aspiration during anaesthesia

Without targeted policy interventions, such as expanded insurance coverage or income-based subsidy programs, the benefits of GLP-1 medications may continue to accrue disproportionately to higher-income populations, leaving behind the very communities most affected by obesity